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Oral squamous cell carcinomas are associated with a poor prognosis, which may be partly due to 
functional impairment of the immune response. Lymphocyte recruitment to the tumor site is facilitated by 
high-endothelial venules, whereas expression of programmed-death ligand 1 (PD-L1) can impair T cell 
function.  Thus, we hypothesize that these factors are important in shaping the immune response in oral 
squamous cell carcinoma. In the present study, we characterized the immune infiltrate in formalin-fixed, 
paraffin-embedded tumor samples from 75 oral squamous cell carcinoma patients. We used 
immunohistochemistry to determine the distribution of immune cell subsets, high-endothelial venules and 
PD-L1, as well as quantitative real-time polymerase chain reaction to assess the expression of 
inflammatory cytokines and chemokines associated with lymphocyte trafficking. Finally, we calculated 
correlations between the presence of immune cell subsets, the gene expression patterns, high-endothelial 
venules, PD-L1 and the clinicopathological parameters including patient survival. The presence of high-
endothelial venules correlated with increased number of CD3+ T cells and CD20+ B cells, higher levels of 
the chemokines CXCL12 and CCL21, and lower levels of CCL20, irrespective of the tumors’ T-stage. In 
univariate analysis, high levels of CD20+ B cells and CD68+ macrophages, positive high-endothelial 
venule-status, and low T- and N-stages predicted longer patient survival. However, only the presence of 
high-endothelial venules and a low T-stage were independent positive prognosticators. This indicates that 
high-endothelial venules are important mediators and a convenient marker of an antitumor immune 
response in oral squamous cell carcinoma. Our findings suggest that these vessels are a potential 
immunomodulatory target in this type of cancer. PD-L1 staining in tumor cells correlated with lower T-
stage, increased infiltration of CD4+ cells and higher expression of several inflammation-related 
cytokines. Thus, oral squamous cell carcinomas rich in CD4+ cells may preferentially respond to PD-
1/PD-L1 blockade therapy. 
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The majority of oral cancers are squamous cell carcinomas, and their incidence is increasing in many 
Western countries (1). Oral squamous cell carcinoma are regarded as aggressive cancers, but tumors of the 
same stage show substantial heterogeneity in progression and response to treatment. Unlike many other 
cancers, such as breast-, lung- and colorectal cancer, there are no reliable biomarkers that predict the 
aggressiveness or treatment response of an individual oral squamous cell carcinoma (2-4).  
The immune system is an important and complex regulator of tumor evolution. Immune suppression 
promotes tumorigenesis in murine models (5); and likewise, a number of cancers occur with increased 
frequency and aggressiveness in immunocompromised patients (6). Mutated cell express altered proteins 
or tumor-specific antigens that usually evoke an immune response (7). However, the intensity and 
composition of the tumor-associated inflammation varies between patients and may affect prognosis, as 
demonstrated in melanoma, breast and ovarian cancer (8-10). For some cancers, including melanoma and 
head and neck cancer, an inflamed and a non-inflamed phenotype have been described (11, 12). Inflamed 
tumors are characterized by marked T cell infiltration and high expression of chemokines that can recruit 
effector T cells, and are generally associated with a favorable prognosis (13). Non-inflamed tumors, on the 
other hand may be linked to defective recruitment of immune cells to the tumor microenvironment, and 
predict a poor outcome. Lymphocyte extravasation can be regulated by high-endothelial venules, which 
are blood vessels  expressing  peripheral node addressin that binds L-selectin on circulating naïve 
lymphocytes (14). High-endothelial venules are present in secondary lymphoid organs, and develop 
regularly in chronically inflamed tissue (15). We have previously reported that the presence of high-
endothelial venules is associated with improved survival in oral squamous cell carcinomas (16), which is 
in line with results from studies on melanoma and breast cancer (17, 18). However, these vessels are 
plastic, and their remodeling into regular venules may impair lymphocyte recruitment and precede sentinel 
lymph node metastasis (19, 20).  
Although oral squamous cell carcinomas are mostly of the inflamed phenotype suggesting effective 
immune surveillance (13), these cancers are generally associated with poor survival. This could be 
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explained by immune editing mechanisms that  impair infiltrating lymphocytes and allow tumor 
progression despite the apparent immune response (21). Programmed-death ligand 1 (PD-L1) expressing 
cells can induce immune suppression by binding the PD 1 receptor (PD-1) on activated T cells and 
downregulate effector T cell functions (22-24). Reversing immunosuppression through blockade of the 
PD-1/PD-L1 pathway has shown clinical efficacy in various cancers, including oral squamous cell 
carcinoma (25-27). However, studies on the prevalence and prognostic role of PD-L1 expression in oral 
squamous cell carcinoma are limited, and conflicting results are reported (22, 28, 29). To date, it remains 
unclear why only a subset of patients respond to PD1/PD-L1 blockade treatment. 
In a cohort of 75 oral squamous cell carcinoma patients, we recently demonstrated that advanced stage 
tumors with high-endothelial venules present were associated with a more pronounced inflammatory 
response and longer patient survival compared to their high-endothelial venule-negative counterpart (16). 
In the present study on the same patient cohort, we explored the hypothesis that high-endothelial venules 
are master regulators of tumor immunity in oral squamous cell carcinoma by characterizing the immune 
cell infiltration and cytokine expression in relation to presence of such vessels. Furthermore, we analyzed 
the association between the tumors’ PD-L1 expression and the immune response, and examined a 
potential relationship between high-endothelial venules and PD-L1 statuses.   
 
Materials and Methods 
Patients and material 
In this retrospective study, we included 75 patients diagnosed with primary oral squamous cell carcinoma 
in the period 1986-2002 from the archives of the Department of Clinical Pathology, University Hospital of 
North Norway. Follow-ups were continued until January 1st, 2012. Patients were included in the study if 
both clinical data and formalin-fixed, paraffin-embedded tumor specimens (biopsy or surgical resection) 
were available. Only patients with cancers in the oral cavity proper were included, and they were 
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distributed among the following locations: mobile tongue (n=34); floor of the mouth (n=21); the alveolar 
ridge (n=18); buccal mucosa (n= 10); unspecified oral cavity (n= 3). Exclusion criteria were prior 
radiotherapy to the head and neck area as well as previous oral or oropharyngeal cancer. Sixty-eight 
percent of the patients received surgery in combination with radiotherapy, 15% concomitant radiotherapy 
and chemotherapy, 11% surgery in combination with local neck-dissection, five percent none or palliative 
therapy, and one percent were unknown. We retrieved clinical and histopathologic information from the 
patients’ hospital files, pathology reports and the Statistics of Norway, Cause of Death Registry, and have 
earlier published these data in studies analyzing the same patient cohort (16, 30). Pathological tumor 
staging was determined according to the most recent (second to fifth) TNM classification from the 
American Joint Committee on Cancer at the time of diagnosis.  There were no changes in the 
classification of cancers of the lip and oral cavity between the different editions used, so that the 
description in the fifth edition is relevant for all cases (31). We conducted the study in line with the 
REMARK guidelines for tumor marker prognostic studies (32), and following approval from the Regional 
Committee for Medical and Health Research Ethics, Northern Norway (REK-number 22/2007). 
Immunohistochemistry 
We used four-micrometer-thick sections of formalin-fixed, paraffin-embedded tumor specimens from oral 
squamous cell carcinoma patients for immunohistochemical analyses, and performed both automated and 
manual staining methods. Specifications of the primary antibodies as well as their incubation conditions 
are listed in Table 1. We used CD3 as a pan T-cell marker. Various subtypes of T helper and T regulatory 
(Treg) cells express CD4 strongly, whereas monocytes, macrophages and dendritic cells may show weak 
expression. Cytotoxic T cells, and to less extent, natural killer cells and subsets of dendritic cells express 
CD8. CD20 is a pan B cell marker, and CD68 is a pan macrophage marker, but it may also stain subsets of 
lymphocytes, fibroblasts and endothelial cells. Mature dendritic cells and, to some extent, pneumocytes 
express DC-lamp/CD208.  
Automated staining. Staining for CD3, CD4. CD8, CD20, CD68 and PD-L1 was done in the automated 
slide stainer Ventana Benchmark, XT (Ventana, Tucson, AZ, USA) at the Diagnostic Clinic – Clinical 
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Pathology, University Hospital of North Norway, accredited according to the ISO/IEC 15189 standard for 
the respective stainings, as previously published (30). Briefly, for antigen retrieval, deparaffinized and 
blocked sections were heat-treated in 0.01 M sodium citrate buffer at pH 6.0. A cocktail of HRP labelled 
goat anti-mouse IgG/IgM and mouse anti-rabbit secondary antibodies (Ventana UltraView Universal DAB 
Detection Kit, #760-500, Roche) were used for visualization with diaminobenzidine. As these procedures 
are automatized, the manufacturer controls the incubation time of secondary antibodies. In every run, one 
slide with known positivity for the different antibodies (tonsil or lymph node) was added as control. 
Automated staining runs for PD-L1 included in addition a negative control slide with rabbit monoclonal 
negative control Ig (#790-4795, Ventana) for each patient. DC-LAMP staining was performed in the 
Ventana Discovery ULTRA autostainer (Ventana). After dewaxing, cell conditioning-1 solution (CC1) 
(#950-124, Ventana) was applied for antigen retrieval for 32 minutes at 95°C. Endogenous peroxidase was 
blocked by discovery inhibitor CM (#760-4840, Ventana). After incubation with the DC-LAMP primary 
antibody, the pre-diluted secondary antibody (OmniMap anti-mouse HRP; #760-4310, Ventana) was 
loaded for 20 minutes followed by HRP amplification and visualization by ChromoMap DAB (#760-159; 
Ventana). Counterstaining was performed using the Hematoxylin II counterstain reagent (#790-2208, 
Ventana). Metastatic lymph node tissue micro-array slides of lung cancer were used as positive control. 
Giemsa staining was performed using BenchMark Special Stains, an automated slide stainer from 
Ventana. In every run, one slide with known positivity for the stain was added as control. 
Manual staining. Peripheral node addressin staining for the detection of high-endothelial venules was 
performed as previously described (30). In brief, sections were deparaffinized, rehydrated, subjected to 
heat-induced antigen retrieval, blocked and incubated with the peripheral node addressin primary 
antibody. Next, the sections were incubated with HRP-labelled goat anti-rat light chain secondary 
antibody (#AP202P, Millipore, Temecula, CA, diluted 1:250, incubated 30 minutes) and 
diaminobenzidine (Dako EnVision + System-Horseradish Peroxidase, Dako,) before being counterstained 
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with Harry’s hematoxylin (Sigma-Aldrich, St. Louis, MO). Human lymph node specimens were used as 
positive control, and specimens with the primary antibody omitted served as negative control. 
Immunohistochemical evaluation 
Two trained, independent observers (either EHO and AMW, or SES and IKE) who were blinded to the 
clinical outcome evaluated the immunohistochemical stainings quantitatively and semi-quantitatively, as 
illustrated in the flow chart of Figure S1. We assessed inter-observer variations for all stainings except 
DC-Lamp and PD-L1, and the results are listed in Table S1. Agreement was reached by reevaluation and 
discussion in case of differing scores. For DC-Lamp and PD-L1, the two investigators reached consensus 
when evaluating the slides together. Micrographs were taken with a Leica DFC 420 camera on a Leica 
DM2000 microscope (Leica, Wetzlar, Germany). Presence of high-endothelial venules was assessed as 
earlier published (16). Briefly, we scanned the peripheral node addressin stained tumor-adjacent tissue at 
low power magnification (100×) to identify five areas with high density of high-endothelial venules 
(hotspots). Micrographs of these hotspots were taken at high power magnification (400×), and the mean 
number of high-endothelial venules per section was calculated for each patient by dividing the sum of 
these vessels in the five hotspots by five. The median number of high-endothelial venules per hotspot for 
all patients served as cutoff for positive and negative count. Figure S2 shows a micrograph of tumor 
associated high-endothelial vessels. Giemsa staining was used to identify mast cells and eosinophils as 
cells with round nuclei and blue/purple granules or cells with lobulated nuclei and bright orange/pink 
granules, respectively. For each of the cell types, five hotspots in the tumor stroma were identified at low 
power magnification, and micrographs were taken at 400× magnification. The total cell number in the 
hotspots was counted and the mean number calculated. The cutoff for high versus low count was defined 
as the median number for the patient cohort, which was 10 for eosinophils and 3 for mast cells. We scored 
the CD3+, CD4+, CD8+, CD20+ and CD68+ stainings semi-quantitatively, as it was impossible to apply a 
quantitative scoring system in densely stained areas. First, we identified the invasive margin of the tumor 
at low power magnification (100×), and micrographs were taken at 400× magnification, capturing every 
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second visual field of this area. Thus, the number of microscope fields depended on the tumor size. We 
developed a four-degree scoring scale for the different cell subsets as illustrated in Figure S3, and assigned 
each micrograph a score: 0 = no or almost no infiltration; 1 = mild infiltration; 2 = moderate infiltration; 3 
= heavy infiltration. In cases where evaluation was difficult because of weak staining or non-specific 
background staining, the positively stained cells were counted, and the scores determined according to the 
respective cutoff. We calculated a mean score for each section before dichotomizing as low or high if it 
was 0-1.49 or 1.5-3, respectively. PD-L1 expression was assessed based on the percentage of positively 
labeled tumor cells in each section, and was classified as follows: 0 (labelling in ≤5% of cells), 1 
(labelling in >5% and ≤10% of cells), 2 (labelling in >10% and ≤ 50% of cells), 3 (labelling in >50% of 
cells). Expression of DC-LAMP was found only in inflamed areas of the tumor stroma and was scored as 
not expressed (0), slightly expressed (1), moderately expressed (2) or strongly expressed (3) based on 
semi-quantitative evaluation. Both PD-L1 and DC-LAMP scores were subsequently grouped into 2 
categories: low expression (0 or 1) and high expression (2 or 3).  
RNA extraction and quality control 
RNA extraction was performed to evaluate gene expression of cytokines. In cases with sufficient residual 
tumor material, we isolated total RNA from formalin fixed, paraffin embedded oral squamous cell 
carcinoma tissue blocks using the High Pure FFPET RNA Isolation Kit (Roche, Mannheim, Germany) 
following the manufacturer’s instructions. In brief, up to 4 consecutive, 5-10 micrometer thick sections 
from each block were deparaffinized and digested with proteinase K, followed by multiple silica based 
column purification steps and DNAse I treatment. The RNA on the column was washed several times 
before being eluted in 20-35 µl elution buffer. We used a mixture of RNA isolated from three different 
fresh frozen (in liquid nitrogen) human lymphoma specimens as a positive control for further qPCR 
analyses. The RNeasy Fibrous Tissue mini Kit (Qiagen, Hilden, Germany) was used for RNA isolation 
according to the manufacturer’s protocol. Briefly, the tissue was homogenized using a TissueLyser 
(Qiagen, Hilden, Germany) before digestion with proteinase K and centrifugation. The supernatant was 
washed and treated with DNAse I on a miniature column, and the RNA eluated in 50 µl nuclease free 
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water. We measured total RNA quantity and purity on the NanoDrop spectrophotometer (Thermo 
Scientific, Wilmington, DE, USA), and assessed RNA integrity using the Experion automated 
electrophoresis system (Bio-Rad Laboratories, Hercules, USA).  
Real-time quantitative PCR (qPCR) 
We used the QuantiTect Reverse Transcription kit (Qiagen, Hilden, Germany) to reverse transcribe 100-
200 ng total RNA into cDNA, which was subsequently diluted 1:15 in nuclease-free water. QPCR was 
performed in duplicates or triplicates using the Light Cycler 96 instrument (Roche, Mannheim, Germany). 
Target cDNA was amplified through 40 cycles in 20 µl reactions containing 1× FastStart Essential DNA 
Green Master (Roche), 10 µl diluted cDNA (1:15), and 300nM  primers (Table S2). Melting curve 
analysis was used to verify the specificity of the primers. Controls with the reverse transcriptase omitted  
and non-template controls were included to test for genomic DNA contamination and carry-over products, 
respectively. A positive control consisting of cDNA from three different fresh frozen lymphoid tissues 
was included in each run. The qPCR amplification efficiency for each gene was calculated from the slope 
and correlation coefficient (R2) of regression curves from 2-fold serially diluted cDNA. The ∆∆Ct method 
(33) was used to calculate the relative amount of target mRNA normalized against the geometric mean of 
the reference genes elongation factor 1 alpha (eF1a), ribosomal protein L27 (RPL27), and ribosomal 
protein S13 (RPS13). We used geNorm analyses (34) to detect the three most stably expressed reference 
genes, B-actin, and Beta 2 macroglobulin were discarded. For association with high-endothelial vessel and 
PD-L1 statuses, we present the results as fold increase compared to the mean of the group with the lowest 
gene expression (+/- standard error of mean) For survival and correlation analyses, we dichotomized the 
results in low and high expression based on the median of fold increase as cutoff. 
Statistical Analysis  
We used SPSS software version 22.0 for Windows (IBM, Armonk, NY) and Microsoft Excel 2013 
(Microsoft, Redmond, WA) for all calculations. Inter-observer variability for the various quantitative and 
semi quantitative cell counts was analyzed using the Spearman correlation test, and correlation between 
two variables was assessed by the Fisher’s exact test. We used univariate Kaplan Meier analyses to 
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calculate disease-specific death rates and plot disease-specific survival curves, and the log-rank test to 
evaluate the statistical significance. Multivariate analyses were done using a stepwise forward multiple 
Cox regression model. Linear regression analyses of standard curves derived from serially diluted cDNA 
were used to estimate qPCR amplification efficiency. The significance level was set at P < 0.05, and the 
borderline significance level at P < 0.09. 
 
Results 
High-endothelial venules predict T and B cell infiltration into oral squamous cell carcinomas  
We recently demonstrated a correlation between the presence and morphology of high-endothelial venules 
and the intensity of the inflammatory infiltrate in oral squamous cell carcinomas (16). Now, to determine 
the composition of the immune infiltrate, we immunohistochemically stained tumor sections from 75 oral 
squamous cell carcinoma patients with antibodies against the following immune cell markers: CD3 (pan 
T-cell); CD4 (T-helper, Treg cells and macrophages); CD8 (cytotoxic T cell); CD20 (pan B-cell); CD68 
(pan macrophage), and DC-lamp/CD208 (mature dendritic cell). We also performed Giemsa staining to 
identify eosinophils and mast cells.  The high-endothelial venule-negative tumors were generally less 
infiltrated with immune cells compared to the high-endothelial venule-positive tumors (Table 2). The 
differences were statistically significant for CD3+ (P=0.002) and CD20+ (P=0.038) cells, and borderline 
significant for CD8+ cells (P=0.061). 
To determine cytokines associated with high-endothelial venules, we conducted qRT-PCR analysis of 42 
of the 75 oral squamous cell carcinoma tissue samples, of whom 36 were high-endothelial venule-positive 
and 6 were negative (Fig. 1A). The lymphoid chemokines CCL19, CCL21 and CXCL12 were 
significantly higher expressed in the high-endothelial venule-positive compared to the tumors without 
these vessels (P=0.04, P=0.02, and P=0.001, respectively). The inflammatory chemokine CCL20, 
however, was significantly lower expressed in the high-endothelial venule-positive than in the -negative 
tumors (P=0.02). Taken together, our results shows that high-endothelial venule-positive tumors are more 
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heavily infiltrated with lymphocytes than tumors without such vessels, which may be promoted by the 
chemokines CCL19, CCL21 and CXCL12. 
Oral squamous cell carcinomas with high-endothelial venules retain an inflamed phenotype even at high 
T-stage 
In the same oral squamous cell carcinoma patient cohort, we have earlier found that high-endothelial 
venules were present in all T1/T2 tumors, compared to two thirds of the T3/T4 tumors (16), and 
hypothesized that absence of these vessels in advanced tumor stages may suppress the immune reaction. 
To elaborate this theory, we compared the immune cell infiltrate and cytokine expression in the T1/T2 
tumors with the T3/T4 tumors, as well as the T3/T4 tumors subdivided into high-endothelial venule -
positive and -negative. We found a significantly higher amount of infiltrating CD3+ T cells, CD68+ 
macrophages and eosinophils in the T1/T2 tumors (all high-endothelial venule-positive) compared to the 
T3/T4 tumors (high-endothelial venule-positive and -negative) as presented in Table 2 (P=0.026, P=0.002 
and P=0.035, respectively). Dividing the T3/T4 tumors into high-endothelial venule-positive and -negative 
revealed that the positive had an immune cell infiltrate that resembled the T1/T2 tumors, except for fewer 
CD68+ cells in the T3/T4 tumors (P=0.014). In contrast, the high-endothelial venule-negative T3/T4 
tumors showed lower scores than T1/T2 tumors for all immune cell subsets analyzed, except CD4+ cells 
and DC-lamp + dendritic cells that were not significantly different. 
QRT-PCR analysis of 28 T1/T2 tumor samples (all high-endothelial venule-positive) and 13 T3/T4 tumor 
samples (high-endothelial venule-positive, n=7; high-endothelial venule-negative, n=6) revealed higher 
levels of CCL21 and CXCL12, and lower levels of CCL20 in the T1/T2 compared to the T3/T4 tumors 
(P=0.04, P=0.02, and P=0.01, respectively; Fig. 1B). In accordance with the results from immune cell 
analyses, the high-endothelial venule-positive T3/T4 tumors displayed no statistically significant or 
borderline significant differences to the T1/T2 tumors’ cytokine expression (Fig. 1C). The high-
endothelial venule-negative T3/T4 tumors, however, had significantly lower expression of CCL21 and 
CXCL12 and higher expression of CCL20 (P=0.02; P=0.04; P=0.01; Fig. 1D) than the T1/T2 tumors. 
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Together, our results suggest that the presence of high-endothelial venules supports an inflamed 
phenotype even in large (T3/T4) tumors.  
T cell infiltration predicts an immune cell rich tumor microenvironment and is associated with CCL19, 
CXCL12 and lymphotoxin (LT) b expression  
Cytokines, chemokines and cells of the innate and adaptive immune system interact in complex attraction, 
activation and inhibition networks. To reveal putative regulatory mechanisms in the oral squamous cell 
carcinoma immune infiltrate, we performed correlation analyses between the expression level of 
cytokines, the various immune cell scores, and the clinicopathological variables. The 
immunohistochemical score for CD3+ T cells showed statistically significant, positive correlations with 
all other immune cells analyzed except for mast cells (Fig. 2A). There were few significant correlations 
between the other immune cell subsets. With the exception of CXCL8, CCL20 and IL-1β, we found 
numerous positive, significant correlations between the expression levels of the different cytokines 
analyzed (Fig. 2B). Lymphocyte score (CD3+, CD4+, CD8+ and CD20+ cells) showed significant 
positive correlation with one or several of the cytokines CCL19, CXCL9, CXCL10, CXCL12, CXCL13 
and LTb (Fig. 2C). None of the cytokines was significantly correlated with the number of CD 68+ 
macrophages, DC-lamp+ dendritic cells or mast cells, suggesting that these cells are regulated by 
mechanisms distinct from the other studied immune cell populations. Correlation data of the patients’ 
clinicopathological variables with immune cell scores and cytokine expression levels are presented in 
Table S3. Of note, the group size for many of the variables is small, smoking history and alcohol 
consumption are patient reported data, and treatment choice is strongly influenced by tumor stage and co-
morbidity. Altogether, our results show that high numbers of CD3+ T cells in oral squamous cell 
carcinoma is correlated with increased infiltration of a number of other immune cells, and suggest that the 
cytokines CCL19, CXCL12 and LTb may have a prominent role in promoting immune cell infiltration 




PD-L1 expression in oral squamous cell carcinoma cells correlates with increased infiltration of CD4+ 
cells and small tumor size 
Cancer cells may escape immune surveillance by expressing PD-L1, which induces apoptosis in PD-1 
expressing T-lymphocytes, most notably cytotoxic T-cells. PD-1/PD-L1 checkpoint blockade has shown 
promising results in various types of cancer, but only subgroups of patients respond to the treatment. To 
increase the understanding of PD-L1 expression and its association with the immune microenvironment, 
we analyzed PD-L1 expression in 45 tumors, randomly chosen from the 75 oral squamous cell carcinoma 
patient cohort, and determined correlation to infiltrating immune cells, cytokine expression and the 
presence of high-endothelial venules. Eighteen (40%) of the 45 tumor sections stained positive for PD-L1. 
The staining was either membranous and/or cytoplasmic as demonstrated in Figure S4. We did not assess 
PD-L1 positivity of stromal cells because of diffuse staining. Tumors with high PD-L1 expression showed 
increased infiltration of CD4+ and CD8+ cell compared to those with low PD-L1 expression (P=0.025 and 
P=0.066, respectively; Table 3). They also expressed higher levels of a number of cytokines including 
CCL19, CCL21, CXCL9, CXCL10, CXCL13, and LTb (P=0.006, P=0.010, P<0.001, P<0.001, P<0.001 
and P=0.011, respectively; Fig. 3). PD-L1 score was not correlated with patients’ survival (P=0.207; Table 
S4). The T3/T4 tumors had significantly lower PD-L1 immune score than the T1/T2 tumors (P=0.024; 
Table 2). Dividing the T3/T4 tumors into high-endothelial venule-positive and -negative revealed that all 
positive T3/T4 tumors had low PD-L1 expression, whereas the negative showed no statistically significant 
difference in PD-L1 expression compared to the T1/T2 tumors (P=0.010 and P=0.386, respectively). Our 
results demonstrate that PD-L1 expression in tumor cells is associated with a tumor microenvironment 
rich in CD4+ cells and inflammatory cytokines, and that high-endothelial venules are negatively 
correlated with PD-L1 in large tumors (T3/T4). 
 
High-endothelial venules are more powerful prognosticators than the N-stage and separate components of 
the oral squamous cell carcinoma immune infiltrate 
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Many components of the immune infiltrate have been suggested as potential prognosticators for oral 
cancer, but study results are contradictory. Univariate Kaplan-Meier survival analyses of the immune cell 
scores and cytokine expression levels in our oral squamous cell carcinoma cohort showed that high 
numbers of CD20+ B cells and  CD68+ macrophages were significant prognosticators for longer 5-year 
survival (P=0.002 and P=0.027, respectively; Fig. 4 and Table S4). We have  previously reported that the 
high-endothelial venule status, the tumor site as well as the T- and N-stages were significant prognostic 
factors in the same patient cohort (16). All variables that were significantly associated with disease-
specific death in univariate analyses were entered into multivariate Cox regression analyses. The 
proportional hazards assumption was fulfilled for all variables (Figure S5 and (16)). Only the T stage 
(P<0.001) and the high-endothelial venule status (P=0.002) were independent predictors for disease-
specific death (Table 4). These results suggest that high-endothelial venules are more important prognostic 
factors than the N stage and the subsets of the immune infiltrate assessed in this study.  
 
Discussion 
In this study, we show that the presence of high-endothelial venules is indicative of a favorable immune 
microenvironment in oral squamous cell carcinoma, and that these vessels seem to counter-act 
immunosuppressive mechanisms and improve patient survival irrespective of the tumors’ T-stage. PD-L1 
expressing tumor cells correlated positively to a tumor microenvironment rich in CD4+ cells, but had no 
prognostic significance. Our results suggest that high-endothelial venules have a pivotal role in shaping an 
antitumor immune response in oral squamous cell carcinoma, and that PD-1/PD-L1 targeted 
immunotherapy might be specifically successful in patients with tumors rich in CD4+ cell. To the best of 
our knowledge, this is the first study to investigate jointly the role of PD-L1 and high-endothelial venules 




High density of tumor-associated high-endothelial venules has earlier been associated with improved 
survival and inflammation in several cancers including melanoma, oral- and breast cancer (16, 17, 35), 
and in the present study, we aimed to determine the composition of the high-endothelial venule associated 
immune infiltrate in oral squamous cell carcinoma. We found that the high-endothelial venule-positive 
tumors were heavily infiltrated by CD3+ T cells, CD8+ cytotoxic T cells  and CD20+ B cells, which is in 
accordance with previous findings in melanoma and breast cancer (17, 18). Infiltration of CD8+ cytotoxic 
T cells, and especially a high CD8+/Treg ratio have been associated with a favorable prognosis in a 
variety of human solid tumors including ovarian, cervical and oral cancer (36-38). However, of the 
immune cell subsets analyzed in our study, only increased infiltration of CD20+ B cells and CD68+ 
macrophages were significantly correlated with improved patient outcome in univariate analyses. The 
presence of B cells has earlier been associated with positive outcome in head and neck cancer patients (39, 
40). B cells mediate a humoral immune response by producing tumor-specific antibodies, and these cells 
often localize and cooperate with T cells to facilitate potent, long-term antitumor responses (41). In 
contrast to our results, previous studies have mainly found a negative association between macrophages 
and patient survival in oral cancer (42-44). The conflicting results may be due to differences in 
immunohistochemical procedures and scoring. Besides, tumor-associated macrophages appear in different 
functional states that may vary between tumors and within specific tumor areas (45, 46), and the pan-
macrophage marker CD68 does not distinguish between these phenotypes. The CD68 antibody, as well as 
several of the other antibodies used in this study, are not strictly specific for a single cell type. Accurate 
assessment of immune cell subsets requires multiple markers for each subtype, which is laborious and 
costly to incorporate in a day-to-day routine clinical practice. In the present study, only the high-
endothelial venule- and T-statuses were independent positive prognosticators for 5-year disease-specific 
survival. This indicates that these vessels are more relevant as prognostic markers than other components 
of the tumor microenvironment analyzed, and strengthens their role as a potent surrogate marker of an 
effective antitumor immune response. Immunohistochemical detection of high-endothelial venules is 
simple and reliable (16), and implementation in clinical pathology practice could thus be straightforward. 
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Chemokines in and around high-endothelial venules are thought to be crucial for lymphocyte 
extravasation into lymphoid organs (47). In the present study, the gene expression of the lymphoid 
chemokines CXCL12, CCL19 and CCL21 was upregulated in the high-endothelial venule-positive 
tumors. Expression of CXCL12 is an important attractant for naïve T and B cells (48, 49), and has a 
potential role in high-endothelial venule-mediated T cell trafficking into lymph nodes in vitro (50). 
CCL19 and CCL21 interact with CCR7 on lymphocytes, and trigger efficient T cell homing. Thus, 
increased expression of CCL19, CCL21 and CXCL12 in high-endothelial venule-positive tumors supports 
an important role for these vessels in homing of naïve T-cells into oral squamous cell carcinoma. Beside 
their role in lymphocyte homing, CCL19 and CCL21 stimulate migration and maturation of dendritic cells 
(51).  Through lymphotoxin (LT) expression, dendritic cells promote maintenance of a mature high-
endothelial venule phenotype (52). Therefore, downregulation of CCL21 in T3/T4 tumors may be 
indicative of a tumor microenvironment with less infiltrating mature dendritic cells, causing 
dedifferentiation of high-endothelial venules into normal blood vessels (19, 20). However, we did not find 
a significant association between DC-lamp, a marker for mature dendritic cells, and high-endothelial 
venule score. To further study the association between dendritic cells and these vessels, we also performed 
high-endothelial venules/dendritic cell double staining, but faced technical difficulties (data not shown). In 
future studies, assessing markers for tumor angiogenesis could be a valuable supplement to investigate 
high-endothelial venules plasticity, and to shed light on development and maintenance of these vessels in 
advanced tumors. Furthermore, validating the results of the present study in a larger patient cohort with a 
higher number of high-endothelial venules negative tumors is important, as the low number of these 
tumors in the present study may skew the statistical results. 
High-endothelial venule-negative tumors expressed higher levels of the chemokine CCL20 than -positive 
tumors. CCL20 attracts cells expressing the CCR6 receptor, such as dendritic cells and memory and 
effector T-cells. Several studies have found that CCL20 is a chief attractant of  Treg cells, a distinct 
lineage of CD4+ T cells that suppresses anti-tumor immune responses (53-55).  Interestingly, tumor cells 
17 
 
may also express CCR6, and accordingly, CCL20 have been associated with migration and metastases of 
cancer cells (56).  We did not specifically stain for Treg cells nor CCR6, but speculate that the 
downregulation of CCL20 in high-endothelial venule-positive oral squamous cell carcinomas could help 
sustain an anti-tumor immune response by avoiding recruitment of Treg cells. This would be interesting to 
investigate in future studies. In summary, we show that both the early and the advanced high-endothelial 
venule-positive tumors displayed higher levels of tumor-suppressive components of the immune infiltrate 
than the negative. Along with the vessels’ independent prediction of improved survival, this suggests that 
high-endothelial venules promote a tumor-suppressive immune response irrespective of the tumors’ T-
stage.  
Tumor progression often correlates with immune evasion. In several cancers, including oral squamous cell 
carcinoma, immune suppression may be facilitated by PD-L1 that inhibits T cell functions (22, 23). In the 
present study, tumors with high PD-L1 score showed a significant increase in CD4+ cell infiltration 
(P=0.025). Increased numbers of immunosuppressive CD4+ Treg, as well as dysfunctional T lymphocytes 
have previously been found to predict immunosuppressive properties in oral cancer patients (57-59). We 
also found a borderline significant association between PD-L1+ tumor cells and infiltrating CD8+ cells 
(P=0.066), as well as the expression level of a number of inflammation-related cytokines. This suggests 
that PD-L1 expression by itself does not lead to a non-inflamed tumor environment, but may influence the 
efficacy of the immune reaction. This is in accordance with several other studies that report PD-L1 
expression to be associated with cytotoxic T cells that can induce PD-L1 expression in an interferon 
(IFN)-γ dependent manner (60-62). CXCL9 is an IFN-γ-inducible chemokine, and we found a perfect 
linear relationship between PD-L1 score and CXCL9 expression (r=1; data not shown). HPV/p16 positive 
tumors had significantly lower CXCL9 expression than HPV/p16 negative tumors. A correlation between 
HPV-positivity and PD-L1 expression has previously been reported in oropharyngeal cancer (63). Due to 
the low number of HPV/p16 positive cancers in our study, the correlation between the virus, CXCL9 and 
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PD-L1 expression in oral cancer needs validation in a study with a higher amount of HPV positive 
patients.  
Tumors in the floor of the mouth and tumors of cigarette smokers showed significantly lower PD-L1 
expression than tumors at other subsites in the oral cavity and tumors of patients who were non-smokers. 
In the same patient cohort, we have previously reported a correlation between alcohol and tobacco 
consumption and tumors in the floor of the mouth (64). Furthermore, tumors in the floor of the mouth 
expressed less CCL21 than tumors in the other anatomical sites (Table S5), and tumors with low PD-L1 
expression expressed lower levels of CCL21 than tumors with strong PD-L1 expression (Figure 3). 
Whether there is a direct effect of CCL21 and/or tobacco on PD-L1 expression would be interesting to 
investigate in future studies.   Interestingly, high PD-L1 expression was also correlated to a lower T-stage 
(P=0.037), and we found a significantly lower score of PD-L1 expressing tumor cells in the high-
endothelial venule-positive T3/T4 compared to the T1/T2 tumors (P=0.010). This may suggest that high-
endothelial venule-positive large tumors have overcome PD-L1 mediated immunosuppression, which 
could contribute to the increased survival of patients with high-endothelial venules-positive T3/T4 tumors. 
PD-1/PD-L1 blockade is a new immunotherapeutic approach in the combat against cancer, and the clinical 
success of this treatment correlates to some extent with the tumors’ PD-L1 expression (25-27). It can be 
speculated that PD-L1 expressing T1/T2 tumors and high-endothelial venule-negative T3/T4 tumors with 
marked T cell infiltration are good candidates for PD-1/PD-L1 checkpoint targeting therapies.  
In conclusion, we show that high-endothelial venules are markers of a favorable anti-tumor immune 
microenvironment in oral squamous cell carcinoma, and stronger prognosticators than other subsets of the 
immune infiltrate. As detection of these vessels is easy and reliable, high-endothelial venule status may 
serve as a valuable supplement to stratify oral squamous cell carcinoma patients for targeted therapeutic 
approaches. Oral squamous cell carcinomas are generally immunosuppressive tumors with poor patient 
outcome. Understanding the mechanisms that drive immune cell recruitment and generate effective anti-
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tumor responses may provide opportunities to develop new immunomodulatory targets and thereby 
increase the consistently low survival rates of patients with oral cancer. 
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Figure legends 
Figure 1. Log2 fold gene expression of various chemokines in formalin-fixed paraffin-embedded 
oral squamous cell carcinoma tissue samples. Comparison of the following groups: A) high-endothelial 
venules (HEV) positive versus high-endothelial venules (HEV) negative tumors, B) T1/T2 versus T3/T4 
tumors, C) T1/T2 versus T3/T4 tumors with high-endothelial venules (HEV) and D) T1/T2 versus T3/T4 
tumors without high-endothelial venules (HEV). All T1/T2 tumors were high-endothelial venules positive. 
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Error bars indicate +/- standard error of the mean, and * indicates p < 0.05. The P-value was calculated 
using two sample T-test. 
Figure 2. Heatmaps of Pearson correlation coefficients. The heatmaps show results from bivariate 
correlation analyses of the following parameters in the oral squamous cell carcinomas: A) immune cell 
immunohistochemical scores, B) gene expression pattern, and C) gene expression pattern and immune cell 
immunohistochemical scores. White crosses in the heatmaps show significant correlation between the 
different variables with p < 0.05. 
 
Figure 3. Comparison of log2 fold gene expression of various chemokines and cytokines in formalin-
fixed paraffin-embedded oral squamous cell carcinoma tissue samples with high and low 
programmed-death ligand 1 (PD-L1) score. Error bars indicate +/- standard error of the mean, and * 
indicates p < 0.05. The P-value was calculated using two sample T-test. 
 
Figure 4. Kaplan-Meier analysis of 5-year disease-specific survival for patients with oral squamous 
cell carcinoma. High counts of A) CD20+ B cells and B) CD68+ macrophages were associated with 
improved survival (P = 0.002 and P = 0.027, respectively). The Kaplan-Meier curves show a 5-year 
disease-specific survival rate of 81.4% for CD20 high versus 50% for CD20 low tumors (A), and 80.6% 








Table 1: Primary antibodies for immunohistochemistry. 
Target Primary antibody Dilution Incubation time 
T cells Rabbit monoclonal anti-CD3, clone 2GV6, 
Ventana Medical Systems, Tucson, AZ 
Pre-diluted 16 min 
T helper and T 
regulatory cells 
Rabbit monoclonal anti-CD4,clone SP35, Ventana 
Medical Systems 
Pre-diluted 32 min 
Cytotoxic T cells Rabbit monoclonal anti CD-8, clone SP57, 
Ventana Medical Systems 
Pre-diluted 32min 
B cells Mouse monoclonal anti-CD20, clone L26, Ventana 
Medical Systems 
Pre-diluted 16 min 
Macrophages Mouse monoclonal anti-CD68, clone KP-1, 
Ventana,  
Pre-diluted 12 min 
Dendritic cells Mouse anti-DC-LAMP/CD208, clone 104G4, 
#DDX0190, Dendritics, Dardilly, France 
1:50 32 min 
PD-L1+ tumor cells Rabbit monoclonal anti-PD-L1, clone SP263, 
#790-4905, Ventana Medical Systems 
Pre-diluted 16 min 
High-endothelial venules Rat anti-PNAd, clone MECA-79, Biolegend, San 
Diego, CA 
1:25 30 min 
 
Table 2: Comparison of low versus high counts of infiltrating immune cells in OSCC patients* with and without 
high-endothelial venules (HEV) using Fisher’s exact test.  
 
  All tumors T1/T2  T3/T4  
 HEV+ HEV- all HEV+  all (HEV+/-) HEV+ HEV- 
 no. (%) no. (%) P no. (%) no (%) P no. (%) P no. (%) P 
CD3           
Low 15 (22.4)  6 (85.7) 0.002 11 (21.2) 10 (47.6) 0.026 4 (28.6) 0.396 6 (85.7) 0.002 
High 52 (77.6) 1 (14.3)  41 (78.8) 11 (52.4) 10 (71.4) 1 (14.3) 
CD4              
Low 44 (65.7) 5 (100.0) 0.170 34 (65.4) 14 (73.7) 0.359 9 (64.3) 0.587 5 (100.0) 0.138 
High 23 (34.3) 0 (0.0)  18 (34.6) 5 (26.3) 5 (35.7) 0 (0.0) 
CD8              
Low 35 (52.2) 5 (100.0) 0.061 28 (53.8) 12 (63.2) 0.336 7 (50.0) 0.517 5 (100.0) 0.057 
High 32 (47.8) 0 (0.0)  24 (46.2) 7 (36.8) 7 (50.0) 0 (0.0) 
CD20              
Low 26 (38.2) 6 (85.7) 0.038 20 (37.7) 12 (57.1) 0.104 6 (42.9) 0.478 6 (85.7) 0.022 
High 42 (61.8) 1 (14.3)  33 (62.3) 9 (42.9) 8 (57.1) 1 (14.3) 
CD68              
Low 33 (48.5) 6 (85.7) 0.109 22 (41.5) 17 (81.0) 0.002 11 (78.6) 0.014 6 (85.7) 0.034 
High 35 (51.5) 1 (14.3)  31 (58.5) 4 (19.0) 3 (21.4) 1 (14.3) 
DC-lamp           
Low 32 (51.6) 5 (71.4) 0.279 25 (53.2) 11 (52.4) 0.579 6 (42.9) 0.354 5 (71.4) 0.314 
High 30 (48.4) 2 (28.6)  22 (46.8) 10 (47.6) 8 (57.1)  2 (28.6)  
Eosinophils              
Low 37 (55.2) 6 (85.7) 0.227 26 (50.0) 16 (76.2) 0.035 10 (71.4) 0.129 6 (85.7) 0.082 
High 30 (44.8) 1 (14.3)  26 (50.0) 5 (23.8) 4 (28.6) 1 (14.3) 
Mast cells              
Low 32 (47.8) 6 (85.7) 0.108 25 (48.1) 13 (61.9) 0.209 7 (50.0) 0.568 6 (85.7) 0.068 
High 35 (52.2) 1 (14.3)  27 (51.9) 8 (38.1) 7 (50.0) 1 (14.3) 
PD-L1           
Low 23 (59.0) 4 (66.7) 0.544 15 (50.0) 12 (85.7) 0.024 8 (100.0) 0.010 4 (66.7) 0.386 
High 16 (41.0) 2 (33.3)  15 (50.0) 2 (14.3) 0 (0.0) 2 (33.3) 
 
 
* Analyses for CD3+ cells, eosinophils and mast cells were carried out in 74 patients, for CD4+ and CD8+ cells 
in 72 patients, for DC-lamp+ cells in 69 patients and for PD-L1+ cells in 45 patients. All other analyses included 
75 patients. 
High endothelial vessels is abbreviated HEV in the table. 
Table 3: Comparison of low versus high numbers of infiltrating immune cells in oral squamous cell carcinoma 
patients* with low and high PD-L1 scoring using Fisher’s exact test. 
 PD-L1 low 
no. (%) 
PD-L1 high 
no. (%) P 
CD3     
  
Low 10 (37.0) 4 (22.2) 
0.237High 17 (63.0) 14 (77.8) 
CD4    
Low 21 (80.8) 8 (47.1) 
0.025High 5 (19.2) 9 (52.9) 
CD8    
Low     18 (69.2) 7 (41.2) 
0.066High 8 (30.8) 10 (58.8) 
CD20    
Low 11 (40.7) 9 (50.0) 
0.379High 16 (59.3) 9 (50.0) 
CD68    
Low 15 (55.6) 9 (50.0) 
0.475High 12 (44.4) 9 (50.0) 
DC-lamp    
Low 14 (58.3) 9 (50.0) 
0.411High 10 (41.7) 9 (50.0) 
Eosinophils    
Low 17 (63.0) 8 (44.4) 
0.179High 10 (37.0) 10 (55.6) 
Mast cells    
Low 13 (48.1) 8 (44.4) 0.525High 14 (51.9) 10 (55.6) 
 
* Analyses for CD4+ and CD8+ cells were carried out in 43 patients and for DC-lamp+ cells in 42 patients. All 
other analyses included 45 patient 
Table 4: Multivariate analysis of 5-year disease-specific death according to Cox’s proportional hazards model*. 
Variable Hazard ratio 95% C.I. P 
T stage (T1/T2 [n= 49] v. T3/T4 [n=20]) 0.121 0.045 – 0.321 <0.001 
HEV (negative [n = 6] v. positive [n = 63]) 0.147 0.044 – 0.490 0.002 





Table S1. Spearman correlation coefficients for inter-observer agreement among EHO and AMW. Correlation 
coefficients were interpreted as follows: 0.7-0.9, good agreement; 0.9-1.0 very good agreement. 
Category Spearman correlation coefficient Interpretation 
CD3+ cells 0.878 Good 
CD4+ cells 0.905 Very good 
CD8+ cells 0.868 Good 
CD20+ cells 0.872 Good 
CD68+ cells 0.724 Good 
Eosinophils 0.817 Good 
Mast cells 0.813 Good 
 
Table S2. Accession numbers and primer sequences of reference and target RNAs. 
Gene Accession no. Full name Primer sequence (5’ to 3’) Size 
(bp) 
Reference RNA 
eF1a NM001402.5 Elongation factor 1 alpha F: TATCCACCTTTGGGTCGCTTT 63 
R: TGATGACACCCACCGCAACT 
RPL27 NM000988.3 Ribosomal protein L27 F: GCTGGACGCTACTCCGGAC 64 
R: CGATCTGAGGTGCCATCATCA 
RPS13 NM001017.2 Ribosomal protein S13 F: AGAGAGCCGGATTCACCGTTT 62 
R: CAATTGGGAGGGAGGACTCG 
Target RNA 




C-C motif chemokine ligand 20 F: TTTTCTGGAATGGAATTGGACA 




C-C motif chemokine ligand 21 F: GCAGCTACCGGAAGCAGGA 61 
R: GGGCAAGAACAGGATAGCTGG 
CXCL8 NM000584.3 C-C motif chemokine ligand 8 F: CTCCAAACCTTTCCACCCCA 64 
R: CGCAGTGTGGTCCACTCTCA 
CXCL9 NM002416.2 C-C motif chemokine ligand 9 F: TGCTGGTTCTGATTGGAGTGC 62 

















Lymphotoxin beta F: GTCACCCCGATATGGTGGACT 78 
R: GCACTCATATTCCCTCACCCC 
TNFa NM000594.3 Tumor necrosis factor alpha F: CACCACTTCGAAACCTGGGA 60 
R: TGGTTGCCAGCACTTCACTG 
Table S3. Comparison of clinicopathologic variables between oral squamous cell carcinoma patients* with low and high numbers of various immune cells using Pearson’s 
Chi-square test. 
 CD3*  CD4  CD8  CD20  CD68  DC-lamp  Eosinophils  Mast cells  PD-L1+ cells  
low high  low high  low high  low high  low high  low high  low high  low high  low high  
 no P no P no P no P no P no P no P no P no P 
Gender 
Male 11  31  0.632 27 14 0.645 24 17  0.558 19  24  0.758 26  17  0.089 19  19  0.504 27 15 0.217 23 19 0.501 17 10 0.619 
Female 10 22   22 9  16  15  13  19   13 19  18  13  16 16  15 17  10 8  
Age at diagnosis, years 
0-59 7 21 0.615 17 11 0.287 13 15 0.214 12 16 0.979 10  18  0.029 14  12  0.977 18  10  0.401 16  12 0.437 13  4  0.079 
≥ 60 14  32   32  12   27  17  20 27  29  18  23 20  25 21  22 24  14 14  
Smoking history 
Never smoker   2  15  0.178 12  5  0.306 9  8  0.946 3  14  0.053 5  12  0.127 7 9  0.376 9  8  0.771 6 11  0.480 7  3  0.022 
Former smoker 3 7   7  3   5  5   5  5   5  5   3  5   6  4   5  5  1  3   
Current smoker 13  29   29  12   24  17   20  23   25 18   23  17  26  16   24  18   19  8   
Unknown 3  2  1  3   2  2   4 1   4  1   4  1   2  3   3  2   0  4  
Alcohol consumption 
Never 2 9 0.541 10 1 0.108 8  3  0.005 4 8  0.567 5 7  0.168 5  5  0.548 7  4  0.793 5 6  0.007 4  2 0.079 
≤ 1 times weekly 6  21   15 12   8  19   10 17   14  13   11  13   15  12   8  19   6  8  
> 1 times weekly or daily 7  13   15  4   15  4   9  11   8  12   10  9   13  7   16  4   10  1   
Unknown 6  10   9  6   9 6   9  7   12  4   11  5   8  8   9  7   7  7  
Tumor site 
Mobile tongue 






































All others** 7 12   10 8   6  12   11  8   12  7  11  8   11  8   11  8  6  8  
Tumor differentiation 
Well 6  22  0.208 19  8  0.225 17  10  0.239 10  18  0.527 15  13  0.894 11  15  0.085 15  13  0.826 11  17  0.269 10  8  0.610 
Moderate 12  29   25  15   19  21   19  23   21  21   22  17   25  16   24 ( 17   13  9   
Poor 3  2   5  0  4  1   3  2   3  2   4  0   3  2   3  2  4  1  
T stage  
T1/T2 11  41  0.062 34  18  0.632 28  24  0.416 20  33  0.215 22  31  0.005 25  22  0.644 26  26  0.084 25  27  0.330 15  15 0.037 
T3/T4 10 11   14  5   12  7  12  9   17  4   11  10   16  5   13  8   12  2  
Unknown 0  1   1  0   0  1  0  1   0  1  1  0   1  0   0  1   0  1  
N stage 
N0 15  35  0.030 31  18  0.424 26  23 0.679 21  30  0.457 26  25  0.483 25  22  0.428 27  23  0.371 25  25  0.736 16  12 0.853 
N+  2 16  13) 4   11  6  7 11  11  7   8  9   11  7   9  9   8  4   
Unknown 4  2   5  1   3 3  4  2  2  4   4  1   5  1  4  2   3  2  
M stage 
M0 18 50  0.226 44  22  0.652 38  28  0.397 28  41  0.353 38  31  0.183 32  31  0.291 38  30  0.398 34  34  0.564 24  16  0.659 
M+  0  1  1  0   0  1   1  0   0  1  1  0   1  0   1  0   1  0  
Unknown 3 2  4 1  2 3  3 2  1 4  4 1  4  1  3 2  2 2  
HPV/p16 
Negative 16  48  0.265 43  21  0.133 35  29  0.401 26  39  0.430 31  34  0.096 31  29  0.141 36  28 0.691 33  31  0.996 22  15 0.095 
Positive 3  3   5  0  4 1   4  2   4  2   2  3  4  2   3  3   4  0  
Unknown 2  2  1  2   1  2   2  2   4  0   4  0  3  1   2  2   1  3   
 
* Analyses for CD3+ cells, eosinophils and mast cells were carried out in 74 patients, for CD4+ and CD8+ cells in 72 patients, for DC-lamp+ cells in 69 patients, and for PD-
L1+ cells in 45 patients. All other analyses included 75 patients. 
** All other anatomical sites includes the following anatomical subsites: Alveolar ridge (n= 18); buccal mucosa (n= 10); unspecified oral cavity (n= 3).    
Table S4. Infiltration of different immune cell subsets* and expression of various genes** in oral squamous cell 
carcinoma patients as predictors for 5-year disease-specific death in univariate Kaplan-Meier analysis. 
  Patients (no. (%)) 5-Year DSD (%) P 
CD3     
  
Low 21 (28.4) 42.9 0.200 High 53 (71.6) 28.3 
CD4       
Low 49 (68.1) 32.7 0.691 High 23 (31.9) 26.1 
CD8  
Low     40 (55.6) 25.0 0.304 High 32 (44.4) 37.5 
CD20       
Low 32 (42.7) 50.0 
0.002 High 43 (57.3) 18.6 
CD68       
Low 39 (52.0) 43.6 
0.027 High 36 (48.0) 19.4 
DC-lamp    
Low 37 (53.6) 37.8 0.639 High 32 (46.4) 31.2 
Eosinophils       
Low 43 (58.1) 37.2 0.187 High 31 (41.9) 25.8 
Mast cells       
Low 38 (51.4) 34.2 0.625 High 36 (48.6) 30.6 
PD-L1+ cells    
Low 27 (60.0) 37.0 0.207 High 18 (40.0) 22.2 
CCL19       
Low 20 (50.0) 25.0 0.592 High 20 (50.0) 40.0 
CCL20       
Low  13 (40.6) 23.1 0.198 High 19 (59.4) 47.4 
CCL21       
Low 24 (66.7) 29.2 0.876 High 12 (33.3) 33.3 
CXCL8       
Low     32 (76.2) 34.4 0.865 High 10 (23.8) 30.0 
CXCL9       
Low 19 (52.8) 26.3 0.724 High 17 (47.2) 35.3 
CXCL10       
Low 35 (89.7) 34.3 0.607 High 4 (10.3) 25.0 
CXCL12       
Low 27 (64.3) 40.7 0.120 High 15 (35.7) 20.0 
CXCL13       
Low 28 (70.0) 39.3 0.367 High 12 (30.0) 25.0 
IL1b       
Low 33 (78.6) 33.3 0.759 High 9 (21.4) 22.2 
LTb    
Low 30 (73.2) 40.0 0.157 High 11 (26.8) 18.2 
TNFa    
Low 20 (51.3) 40.0 0.349 High 19 (48.7) 31.6 
    
* Analyses for CD3+ cells, eosinophils and mast cells were carried out in 74 patients, for CD4+ and CD8+ cells in 72 patients, for DC-lamp+ cells 
in 69 patients and for PD-L1+ cells in 45 patients. All other analyses included 75 patients. 
** The number of patients included in the different analyses varied dependent on availability of patient material.
Table S5. Comparison of clinicopathological variables between oral squamous cell carcinoma patients* with low 
and high expression of various genes using Pearson’s Chi-square test. 
 CCL19  CCL20  CCL21  CXCL8  CXCL9  CXCL10  
low high  low high  low high  low high  low high  low high  
 no  P no P no P no P no P no P 
Gender 
Male 10 16 0.047 8 11 0.837 14 11 0.041 21 6 0.746 11 12 0.429 22 3 0.632
Female 10 4  5 8  10 1  11 4  8 5  13 1  
Age at diagnosis, years 
0-59 5 10 0.102 5 7 0.926 8 6 0.334 10 5 0.280 6 7 0.549 10 4 0.005
≥ 60 15 10  8 12  16 6  22 5  13 10  25 0  
Smoking history 
Never smoker   4 4 0.764 2 6 0.727 6 2 0.392 8 1 0.391 5 3 0.090 7 2 0.550
Former smoker 1 1  1 1  2 0  2 0  0 2  2 0  
Current smoker 12 14  9 10  14 10  20 7  14 9  23 2  
Unknown 3 1  1 2  2 0  2 2  0 3  3 0  
Alcohol consumption 
Never 2 1 0.582 0 3 0.480 3 1 0.968 3 1 0.172 2 1 0.849 4 0 0.197
≤ 1 times weekly 5 9  5 5  8 5  13 1  6 7  9 3  
> 1 times weekly or 
daily 
6 4  4 5  7 3  6 5  5 3  10 1  
Unknown 7 6  4 6  7 3  10 3  6 6  12 0  
Tumor site 
Mobile tongue 


























All others** 6 3  2 7  5 0  8 2  2 5  8 0  
Tumor differentiation 
Well 10 10 0.329 8 8 0.450 11 6 0.589 16 5 0.658 11 8 0.519 19 1 0.399
Moderate 8 10  5 10  11 6  15 4  8 9  14 3  
Poor 2 0  0 1  2 0  1 1  0 0  2 0  
T stage 
T1/T2 13 15 0.490 11 9 0.096 15 11 0.066 22 6 0.688 13 13 0.590 22 4 0.328
T3/T4 7 5  2 9  9 1  9 4  6 4  12 0  
Unknown 0 0  0 1  0 0  1 0  0 0  1 0  
N stage 
N0 14 14 0.135 10 12 0.705 16 9 0.440 21 7 0.949 14 12 0.979 22 4 0.328
N+  3 6  2 5  5 3  8 2  4 4  9 0  
Unknown 3 0  1 2  3 0  3 1  1 1  4 0  
M stage 
M0 17 20 0.198 12 17 0.787 22 11 0.223 29 9 0.793 17 16 0.631 31 4 0.775
M+  1 0  0 0  0 1  1 0  1 0  1 0  
Unknown 2 0  1 2  2 0  2 1  1 1  3 0  
HPV/p16  
Negative 15 18 0.100 12 14 0.349 21 10 0.875 27 7 0.587 16 14 0.049 27 4 0.563
Positive 4 0  1 3  2 1  3 2  3 0  5 0  
Unknown 1 2  0 2  1 1  2 1  0 3  3 0  
 CXCL12  CXCL13  IL1b  LTb  TNFa  
low high  low high  low high  low high  low high  
 no P no P no P no P no P 
Gender 
Male 15 12 0.113 18 8 0.885 23 4 0.161 18 8 0.453 13 13 0.821
Female 12 3  10 4  10 5  12 3  7 6  
Age at diagnosis, years 
0-59 6 9 0.014 9 5 0.563 10 5 0.161 8 7 0.029 8 7 0.839
≥ 60 21 6  19 7  23 4  22 4  12 12  
Smoking history 
Never smoker   6 3 0.236 5 4 0.071 7 2 0.899 5 4 0.305 4 4 0.927
Former smoker 2 0  0 2  2 0  2 0  1 1  
Current smoker 15 12  21 5  21 6  19 7  14 12  
Unknown 4 0  2 1  3 1  4 0  1 2  
Alcohol consumption 
Never 2 2 0.416 2 2 0.660 2 2 0.412 2 2 0.559 2 1 0.924
≤ 1 times weekly 7 7  9 5  12 2  9 4  7 6  
> 1 times weekly or daily 8 3  8 2  8 3  8 3  5 6  
Unknown 10 3  9 3  11 2  11 2  6 6  
Tumor site 
Mobile tongue 






















All others** 8 2  5 4  8 2  8 2  3 6  
Tumor differentiation 
Well 13 8 0.556 14 5 0.496 15 6 0.229 16 5 0.544 10 9 0.987
Moderate 12 7  12 7  17 2  12 6  9 9  
Poor 2 0  2 0  1 1  2 0  1 1  
T stage 
T1/T2 16 12 0.092 19 8 0.290 23 5 0.142 18 9 0.057 14 11 0.494
T3/T4 11 2  9 3  10 3  12 1  6 7  
Unknown 0 1  0 1  0 1  0 1  0 1  
N stage      
N0 16 12 0.387 18 9 0.799 22 6 0.257 18 9 0.362 14 11 0.513
N+  8 2  7 2  9 1  9 1  5 5  
Unknown 3 1  3 1  2 2  3 1  1 3  
M stage      
M0 24 14 0.747 25 11 0.799 31 7 0.127 27 10 0.806 18 17 0.512
M+  1 0  1 0  1 0  1 0  1 0  
Unknown 2 1  2 1  1 2  2 1  1 2  
HPV/p16      
Negative 20 14 0.266 23 9 0.331 29 5 0.061 24 10 0.616 18 14 0.262
Positive 4 1  4 1  2 3  4 1  2 3  
Unknown 3 0  1 2  2 1  2 0  0 2  
 
* The number of patients included in the different analyses varied dependent on availability of patient material 
** All other anatomical sites includes the following anatomical subsites: Alveolar ridge (n= 18); buccal mucosa (n= 
10); unspecified oral cavity (n= 3).     
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Figure S2. Representative immunohistochemical Peripheral node adressin staining for high-endothelial 
vessels in an oral squamous cell carcinoma tissue section.  Peripheral node adressin staining is brown, and cell 
nuclei are stained blue by hematoxylin. Scale bars indicates 40 μm.
 
 
Figure S3. Four-degree scoring scale for semi-quantitative evaluation of different immunohistochemical 
stainings. A) CD3+ cells, B) CD4+ cells, C) CD8+ cells, D) CD20+ cells, E) CD68+ cells. Micrographs of the 
respective immunohistochemically stained cells were assigned to groups 0-3 of the respective scoring schemes. 
Groups 0-1 were evaluated as low and groups 2-3 as high count, respectively. 
 
 
Figure S4. Representative immunohistochemical PD-L1 staining of A) tumor cells and B) stromal cells in 
an oral squamous cell carcinoma tissue section. PD-L1+ cells express membranous and/or cytoplasmatic 
brown staining, and cell nuclei are stained blue by hematoxylin. Scale bars indicate 40 μm.
 
Figure S5. Log minus log plots for proportional hazards checking. A) CD20+ cells, B) CD68+ cells. 
